When the leading biologics all clear the same efficacy bar, the competition moves to dosing interval, route, and what biosimilars have done to the cost of the step in front of them.
A minority of the diagnosed population has moderate-to-severe disease eligible for systemic and biologic therapy, and a meaningful share of those patients also have psoriatic arthritis, which frequently decides which agent is selected. Treatment escalates through topicals and phototherapy to conventional systemics before biologics and oral targeted agents come into scope, so the eligible pool is defined by position in that escalation rather than by diagnosis.
Efficacy has converged at the top of the market. The leading IL-23 and dual IL-17 agents reach the same high response threshold at similar rates, which leaves dosing interval as the principal differentiator between them. An oral targeted agent competes on route rather than on matching biologic response. Where efficacy no longer separates products, the commercial argument moves to burden and convenience, and that is a different kind of case to make.
Biosimilars are reshaping access policy as much as price. As older biologics erode to biosimilar competition, the cost to a payer of requiring a step before approving a branded agent falls, which makes step therapy cheaper to operate and harder to dislodge. Negotiation has separately reset the price of older agents in the class, lowering the reference point against which newer entrants are judged from a second direction.
AXLRx psoriasis reports size the systemic-eligible pool with the arthritis overlap, and read pricing where biosimilar erosion and negotiation compress from both sides.
Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US, and the efficacy bar has moved from PASI 75 to PASI 90. IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2 all hold ground.
Psoriasis affects about 3.0% of US adults, roughly 7.55 million people. Only the moderate-to-severe minority reaches the systemic and biologic therapies that define the commercial market.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together. IRA price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
Bimekizumab already clears PASI 90 in 85% of patients at week 16. A new plaque psoriasis entrant has to win on dosing interval or route, not incremental clearance, against an incumbent price anchor the IRA has already cut 66-67%.
Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026. That is the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once.
About 7.55 million US adults, or 3.0%, have psoriasis, with prevalence higher in White than Black adults at 3.6% against 1.5%. Roughly one in five has moderate-to-severe disease, defined by a PASI of 12 or above or body surface area of 10% or more, and it is that group that is eligible for systemic and biologic therapy. Just under a fifth, 19.7%, have concurrent psoriatic arthritis, which frequently determines which agent is chosen. Treatment escalates from topicals and phototherapy through conventional systemics to biologics and oral TYK2 inhibitors.
Convenience and route. The IL-23p19 inhibitors risankizumab and guselkumab and the dual IL-17A and F inhibitor bimekizumab all set the efficacy bar at PASI 90, reaching 75 to 85% at week 16, which leaves dosing interval as the principal differentiator between them. Secukinumab and ixekizumab anchor the IL-17A class. Deucravacitinib, the first oral TYK2 inhibitor and superior to apremilast, competes on being oral rather than on matching biologic efficacy. Where efficacy converges, the commercial argument moves to burden.
Compressing net price from underneath. Ustekinumab and adalimumab are eroding to biosimilars: nine to ten adalimumab biosimilars entered in 2023, and ustekinumab biosimilars from January 2025 with Wezlana interchangeable. That lowers the cost of the step a payer can require before approving a branded agent, which makes the try-two-fail step design cheaper to operate and therefore harder to dislodge. Biosimilar entry reshapes access policy as much as it reshapes price.
At the older end of it. Medicare negotiated Stelara down to $4,695 from a $13,836 list, a 66% cut, and Enbrel to $2,355 from $7,106, a 67% cut, both effective January 2026. The leading branded IL-23 and IL-17 agents were not in the first cycle. The effect is to reset the reference point against which newer agents are judged, at the same time as biosimilars compress it further. ICER valued the class at roughly $131,000 to $188,000 per QALY in 2018 and urged limits on step therapy.
A sizing read that resolves the moderate-to-severe, systemic-eligible pool and the psoriatic arthritis overlap that steers agent choice; competitive intelligence across the IL-23, IL-17 and oral TYK2 positions where efficacy has converged and dosing interval decides; and a pricing and payer analysis covering step-therapy design, biosimilar erosion, and the negotiated prices now resetting the class reference point. Each is scoped to your asset.